Increasing efficiency of preclinical research by group sequential designs. by Neumann, Konrad et al.
PERSPECTIVE
Increasing efficiency of preclinical research by
group sequential designs
Konrad Neumann1☯, Ulrike Grittner1,2☯*, Sophie K. Piper1,2,3, Andre Rex2,4, Oscar Florez-
Vargas5, George Karystianis6, Alice Schneider1,2, Ian Wellwood2,7, Bob Siegerink2,8, John
P. A. Ioannidis9, Jonathan Kimmelman10, Ulrich Dirnagl2,3,4,8,11,12
1 Department of Biostatistics and Clinical Epidemiology, Charite´ Universita¨tsmedizin Berlin, Berlin, Germany,
2 Center for Stroke Research, Charite´ Universita¨tsmedizin Berlin, Berlin, Germany, 3 NeuroCure Clinical
Research Center, Charite´ - Universita¨tsmedizin Berlin, Berlin, Germany, 4 Department of Experimental
Neurology, Charite´ Universita¨tsmedizin Berlin, Berlin, Germany, 5 Bio-health Informatics Group, School of
Computer Science, The University of Manchester, Manchester, United Kingdom, 6 Centre for Health
Informatics, Macquarie University, Sydney, Australia, 7 Department of Public Health and Primary Care,
Cambridge Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, United
Kingdom, 8 Center for Transforming Biomedical Research, Berlin Institute of Health, Berlin, Germany,
9 Meta-Research Innovation Center at Stanford (METRICS), and Departments of Medicine, of Health
Research and Policy, and of Statistics, Stanford University, Stanford, California, United States of America,
10 STREAM Research Group, Biomedical Ethics Unit, McGill University, Montreal, Canada, 11 German
Center for Neurodegenerative Diseases (DZNE), Berlin Site, Berlin, Germany, 12 German Center for
Cardiovascular Research (DZHK), Berlin site, Berlin, Germany
☯ These authors contributed equally to this work.
* ulrike.grittner@charite.de
Abstract
Despite the potential benefits of sequential designs, studies evaluating treatments or
experimental manipulations in preclinical experimental biomedicine almost exclusively
use classical block designs. Our aim with this article is to bring the existing methodology
of group sequential designs to the attention of researchers in the preclinical field and to
clearly illustrate its potential utility. Group sequential designs can offer higher efficiency
than traditional methods and are increasingly used in clinical trials. Using simulation of
data, we demonstrate that group sequential designs have the potential to improve the effi-
ciency of experimental studies, even when sample sizes are very small, as is currently
prevalent in preclinical experimental biomedicine. When simulating data with a large effect
size of d = 1 and a sample size of n = 18 per group, sequential frequentist analysis con-
sumes in the long run only around 80% of the planned number of experimental units. In
larger trials (n = 36 per group), additional stopping rules for futility lead to the saving of
resources of up to 30% compared to block designs. We argue that these savings should
be invested to increase sample sizes and hence power, since the currently underpowered
experiments in preclinical biomedicine are a major threat to the value and predictiveness
in this research domain.
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Background
Group sizes in preclinical research are seldom informed by statistical power considerations
but rather are chosen on practicability [1, 2]. Typical sample sizes are small, around n = 8 per
group (http://www.dcn.ed.ac.uk/camarades/), and are only sufficient to detect relatively large
sizes of effects. Consequently, true positives are often missed (false negatives), and many statis-
tically significant findings are due to chance (false positives). Such results lack reproducibility,
and the effect sizes are often substantially overestimated (“Winner’s curse”) [2–5]. Therefore,
various research bodies (e.g., National Institutes of Health, United Kingdom Academy of Med-
ical Sciences) have called for increased sample sizes [5, 6], as well as other design improve-
ments in preclinical research. Yet, such calls also potentially antagonize the goal of minimizing
burdens on animals. Here, we propose the use of sequential study designs to reduce the num-
ber of experimental animals required, as well as to increase the efficiency of current preclinical
biomedical research. Moreover, our aim with this article is to bring the existing methodology
of group sequential designs to the attention of researchers in the preclinical field and to clearly
illustrate its potential utility.
Sequential study designs
Conventional study designs in experimental preclinical biomedicine use nonsequential
approaches, in which group sizes are predetermined and fixed, and the decision to either
accept the (alternative) hypothesis or fail to reject the null hypothesis is made after spending
all experimental units in each group. In contrast, a group sequential design is a type of adaptive
design that allows for early stopping of an experiment because of efficacy or futility, based on
interim analyses before all experimental units are spent [7–9], thereby offering an increase in
efficiency.
However, interim analyses come at a statistical cost, and special analysis methods and care-
ful preplanning are required. Traditional frequentist statistics can be used to split the overall
probability of type I error (α–error) to account for multiple testing [10, 11], but Bayesian
methods are particularly suited, as they can incorporate information from earlier stages of the
study. Moreover, Bayesian analysis enables the researcher to use prestudy information as a
basis for the prior information about the measure of interest [8, 9]. As the prior is potentially
subjective and the gained posteriors highly dependent not only on the data but also on the cho-
sen prior, the practice of informed priors is hotly contested. Noninformative priors are an
option to circumvent this concern [12, 13].
Group sequential designs are increasingly used in clinical research [8, 14]. So far, however,
they are virtually nonexistent in preclinical experiments. We performed text-mining of the
complete PubMed Central Open Access subset (time frame: 2010–2014) and found only one
article explicitly describing an original study evaluating a treatment in rats or mice using a
sequential design [15] (S1 Text).
To explore the potential for group sequential designs to increase the efficiency of preclinical
studies, we simulated data for two-group comparisons of different effect sizes and compared
“costs,” measured by the number of animals required for different group sequential designs,
compared to a traditional nonsequential design (S1 Text).
Increase in efficiency
We simulated a mouse experiment in which 36 animals are allocated to two groups. Currently,
in most domains of preclinical medicine, group sizes of ten or less are prevalent, leading to
grossly underpowered studies [4]. A group size of 18 animals per group allows the detection of
a standardized effect size of d = 1, given traditional constraints of alpha = 0.05 and beta = 0.20.
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A block design typically used in this type of study needs to include all animals before data anal-
ysis. In a group sequential design, an interim analysis is conducted, and a predefined set of
rules determine whether the experiment should be continued or not (Fig 1).
Here, we demonstrate only some of many possible analysis approaches (frequentist
sequential with O’Brien–Fleming boundaries [11], with Pocock boundaries [16] [S1 Table],
Bayes Factor, and Bayes credible intervals, Table 1). See Box 1 for other approaches and
references.
The O’Brien–Fleming boundaries in the frequentist sequential approach keep the alpha
level for the final analysis (stage 3) approximately as high as for the classical block design.
Additionally, the same scenarios using Pocock boundaries can be found in S1 Table. It should
be noted that the frequentist approaches refer to null hypothesis significance testing, whereas
the Bayes Factor approach is basically a model comparison, and the other Bayesian approach
uses credible intervals for estimates. These are different methods that might answer different
research questions, as outlined by Morey et al. [27]. However, here, we used all methods for
deriving stopping criteria and decisions about efficacy or futility.
Our simulations showed that in an experimental setting typical for current experimental
biomedicine, if the effect exists, group sequential designs have lower costs because of early
stopping for futility or efficacy (Table 1). With a large true effect size (d = 1) and n = 18 per
group, sequential analyses that stop for significance reduce the costs up to 20%, while the
power of these analyses do not differ from the traditional block design. Underpowered studies
(d = 0.5 scenarios, Table 1) show only approximately 30% power for classical as well as sequen-
tial approaches, while the reduction in costs through sequential design is minor. This stresses
the need for sufficiently powered studies even with sequential analyses. As expected, average
effect sizes among successful experiments are overestimated in the traditional approach and
slightly more so in the sequential design. Larger experiments that can stop for both success
Fig 1. Study design and sequential analysis approach allowing two interim analyses. Stage 1: 33% of samples acquired, stage 2: 66% of
samples acquired, and stage 3: 100% of samples acquired. H0: null hypothesis, P: p-value, Credible interval: specific Bayesian interval of certainty
about an estimate, d: effect size Cohen’s d, αi: significance levels for each stage derived from [11] α1 = 0.0006, α2 = 0.0151, α 3 = 0.0471. Additionally,
we used a Bayes factor approach (Table 1) and Pocock boundaries for the frequentist approach (S1 Table). All sequential approaches used were
calibrated by using simulations to get a type I error of about 5%.
doi:10.1371/journal.pbio.2001307.g001
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and futility show a similar pattern: sequential analysis has similar power as the traditional
approach, while costs are reduced substantially.
Efficiency versus predictive ability in a real-world setting
The simulations above differ from the real-world setting where we, despite setting out to detect
an effect beyond a certain (biological) threshold, never know the true effect size a priori. In
another set of simulations, we therefore assumed a specific distribution of true effect sizes
within the universe of studies that can be performed. Such distributions may vary in different
fields of research. This is relevant because, as with different effect size distributions and the
chance of early stopping an experiment, the predictive probability of a “statistically significant”
signal, i.e., the probability that a significant result really reflects a true effect, is different. To
understand the ability to predict in a real-world setting, we simulated analyses with two
different distributions of effect estimates: one optimistic and one pessimistic (Fig 2, S1 Fig).
Through these simulations, we estimated the probabilities of obtaining an effect of any size
d> 0 or at least size d 0.5 for both the traditional frequentist approach and group sequential
designs. Overall, there are no major differences in these probabilities between the traditional
and sequential approaches—despite the fact that the latter uses fewer animals. More impor-
tantly, this table shows that the main driver behind these probabilities is the a priori distribu-
tion of effect sizes (optimistic versus pessimistic).
Applications of sequential designs
To the best of our knowledge, there are no groups or programs currently implementing
sequential designs in preclinical experimental studies evaluating the efficacy of treatments or
interventions. However, we are aware that the practice of interim analyses is applied informally
when a statistically significant effect is desired but not found, and the analyses are rerun until
significance has been achieved (a practice known as “p-hacking”[28]). Clearly, this practice
inflates false-positive rates, as it violates the preset type I error (α–error) probability by not
accounting for multiple testing in these unplanned interim analyses [10].
Despite the benefits suggested by our simulations, sequential approaches have properties
that may limit their application in preclinical experimental biomedicine. The clearest disad-
vantage of group sequential designs is that each next stage can only be started after the out-
come of the preceding stage is fully assessed and analyzed. Sequential analysis may require
additional resources to set up, regulate, and monitor the independence of interim analyses, as
well as additional statistical expertise. Another consideration is that a step-by-step design
might increase the impact of batch and learning effects. However, the largest obstacle might be
lack of familiarity with these methods in the field and amongst animal ethics committees, edi-
torial boards, and peers. With this paper, we aim to spur the discussion and stimulate others to
consider using sequential designs to increase the efficiency of their studies. Moreover, if in
vivo researchers are to get ethical approval for this approach from their various committees,
this article might help persuade those committees.
We posit that a substantial number of experiments in preclinical biomedicine can be
planned and executed with batch sizes and sufficiently short intervals between treatments and
outcome assessments to render them amenable to group sequential design–based methods
(for an example, see S2 Text). Sequential designs can lead to a substantial reduction in animal
resource. When these savings are invested in increased sample sizes (which, paradoxically,
may not be higher than the current ones), sequential designs have the potential to increase the
predictive ability of preclinical biomedical experiments and to reduce the current unacceptable
levels of waste due to underpowered studies.
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Fig 2. Predictive capabilities of sequential designs compared to traditional nonsequential design for
two different scenarios of potential effect size distributions. Upper left: “optimistic” scenario with more
large effect sizes. Upper right: “pessimistic” scenario with mostly effect sizes of 0. Bottom: Probability of
getting a significant test result reflecting a true effect of d 6¼ 0 or d 0.5, respectively, for the two different
scenarios of effect size distributions. First, the probabilities P(significant) for getting any significant study
results are given, then the corresponding positive predictive values, and, finally, the product of both giving the
corresponding overall probability of getting a significant study result that truly represents an effect of d 6¼ 0 or
d 0.5 (Pdetect true effect). Stopping rules that allowed early stopping for futility or success as given in Table 1.
doi:10.1371/journal.pbio.2001307.g002
Box 1. Points to consider when planning a group sequential design
study
Planning a study design as a group sequential design requires considerations before
starting the study (see [17]; [18]):
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Type of adaptive design
• Group sequential design is one simple type of adaptive design, in which the sample
size is adapted during the study.
• Other types of adaptive design, such as designs with sample size reestimation, adaptive
dose-response designs, treatment selection designs, or adaptive randomization
designs, should be considered as well.
Feasibility
Is it feasible for the planned study:
• to plan larger sample sizes than for fixed designs with the same power (even if the
expected sample size in case of an effect might be lower than for fixed designs)?
• to include additional time for the interim analysis? How many interim steps, and at
which points, are feasible?
Preplanning
This includes:
• clearly specified hypotheses (adaptation should not be done with regard to generating
hypotheses in confirmatory studies),
• decisions about reasons for early stopping: because of efficacy, futility, or both (stop-
ping for futility is more important for larger studies),
• decisions about stopping criteria to reject the null hypothesis/or stop because of futility
at each stage (related to power, type I error, frequentist or Bayesian kind of analysis,
number of stages, sample size at each stage), and
• sample size estimation (depending on kind of statistical test, power, type I error,
assumed effect size, number of stages, stopping criteria).
Type I error (frequentist approach) [19]
• Because of multiple testing, type I error is inflated, but different methods of alpha-
adjustment ensure an overall type I error rate of 0.05:
• Pocock [16]: same significance level at each stage (e.g., three stages (two interim analy-
ses): α = 0.0221 at each stage) (disadvantage: low level at the final stage, which makes it
more difficult to get a significant result).
• O’Brien–Fleming [11]: significance level is very conservative at early stages and almost
0.05 at the final stage (e.g., three stages: α1 = 0.0006, α2 = 0.0151, α3 = 0.0471) (advan-
tage: almost 0.05 at the final stage).
• Haybittle–Peto [20,21]: at all interim stages αi = 0.001, at the final stage: αfinal = 0.05
(advantage: easy to implement and understand and 0.05 level at the final stage, disad-
vantage: hard to stop early).
• Other more flexible approaches with regard to sample size at stages are also possible
(using alpha-spending functions [22]).
Bayesian approaches [23]
• Points of consideration with regard to type of design, feasibility, and preplanning are
similar to designs with frequentist approaches.
• Type I error normally is not of importance in Bayesian frameworks.
PLOS Biology | DOI:10.1371/journal.pbio.2001307 March 10, 2017 7 / 9
Supporting information
S1 Fig. Predictive capabilities of sequential design (Pocock boundaries).
(PDF)
S1 Table. Early stopping for significance or futility using sequential group sequential
design with Pocock-boundaries.
(DOCX)
S1 Text. Supporting materials and methods.
(DOCX)
S2 Text. Illustrative example comparing conventional and group sequential designs using
real experimental data from a pre-clinical study in mice.
(DOCX)
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